Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103
Cell-surface Signaling01:21

Cell-surface Signaling

51.3K
Hormones—or any molecule that binds to a receptor, known as a ligand—that are lipid-insoluble (water-soluble) are not able to diffuse across the cell membrane. In order to be able to affect a cell without entering it, these hormones bind to receptors on the cell membrane. When a first messenger, a hormone, binds to a receptor, a signal cascade is set off, causing second messengers, proteins inside the cell, to become activated, resulting in downstream effects.
51.3K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.3K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

9.7K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potent and Selective IL-4 Inhibitors with Anti-Tumor Activity.

bioRxiv : the preprint server for biology·2026
Same author

A first-in-class small-molecule inhibitor targeting AVIL exhibits safety and antitumor efficacy in preclinical models of glioblastoma.

Science translational medicine·2026
Same author

Alginate Hydrogels with Tunable Degradation.

Macromolecular rapid communications·2025
Same author

Towards directed therapy for fusion-positive rhabdomyosarcoma.

Pharmacology & therapeutics·2025
Same author

Chemical Probe Discovery for DEAD-Box RNA-Binding Protein DDX21 Using Small-Molecule Microarrays.

ACS chemical biology·2025
Same author

Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma.

Nature communications·2024

Related Experiment Video

Updated: May 15, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

1.5K

At The Interface: Small-Molecule Inhibitors of Soluble Cytokines.

Raavi1,2, Angela N Koehler1,2, Arturo J Vegas3

  • 1Koch Institute for Integrative Cancer Research, and Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.

Chemical Reviews
|April 15, 2025
PubMed
Summary

Small-molecule inhibitors offer a promising alternative to biologic therapies for targeting cytokines (immune signaling proteins). These novel compounds address limitations like poor oral bioavailability and high costs, advancing treatment for inflammatory diseases.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.1K
A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

13.6K

Related Experiment Videos

Last Updated: May 15, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

1.5K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.1K
A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

13.6K

Area of Science:

  • Immunology
  • Pharmacology
  • Drug Discovery

Background:

  • Cytokines are key immune regulators implicated in chronic inflammation, cancer, and autoimmunity.
  • Current biologic therapies (e.g., monoclonal antibodies) targeting cytokines are effective but have limitations.
  • Limitations include lack of oral bioavailability, high production costs, and immunogenicity.

Purpose of the Study:

  • To review recent advancements in small-molecule inhibitors targeting soluble cytokines.
  • To highlight strategies for identifying novel small-molecule cytokine ligands.
  • To discuss structural and mechanistic insights into small-molecule cytokine inhibitor activity.

Main Methods:

  • Literature review of recent research on small-molecule cytokine inhibitors.
  • Analysis of strategies for identifying and developing these inhibitors.
  • Examination of structural and mechanistic data for identified inhibitors.

Main Results:

  • Multiple small-molecule inhibitors targeting cytokines have been identified.
  • Several small-molecule inhibitors are currently in clinical evaluation.
  • Novel strategies for targeting challenging protein-protein interactions have emerged.

Conclusions:

  • Small-molecule inhibitors represent a viable alternative to biologics for cytokine targeting.
  • These inhibitors offer potential advantages in oral bioavailability, cost, and immunogenicity.
  • Continued development holds promise for treating cytokine-mediated diseases.